Related Experiment Video
Updated: Jan 19, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Concurrent participation in screening for cervical, breast, and bowel cancer in England
Matejka Rebolj1,2, Dharmishta Parmar2, Roberta Maroni2
1Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Objectives:
To determine how many women participate in all three recommended cancer screening programmes (breast, cervical, and bowel). During their early 60s, English women receive an invitation from all the three programmes.
Methods:
For 3060 women aged 60–65 included in an England-wide breast screening case–control study, we investigated the number of screening programmes they participated in during the last invitation round. Additionally, using the Fingertips database curated by Public Health England, we explored area-level correlations between participation in the three cancer screening programmes and various population characteristics for all 7014 English general practices with complete data.
Results:
Of the 3060 women, 1086 (35%) participated in all three programmes, 1142 (37%) in two, 526 (17%) in one, and 306 (10%) in none. Participation in all three did not appear to be a random event (p < 0.001). General practices from areas with less deprivation, with more patients who are carers or have chronic illnesses themselves, and with more patients satisfied with the provided service were significantly more likely to attain high coverage rates in all programmes.
Conclusions:
Only a minority of English women is concurrently protected through all recommended cancer screening programmes. Future studies should consider why most women participate in some but not all recommended screening.
More Related Videos
Related Concept Videos
09:29Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
05:02Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
10:51Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
10:10Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography

